Aktieanalys

Hansa Biopharma: 5-year efficacy support for Imlifidase/Idefirix ahead of the AMR publication - Redeye

Redeye Publicerad: 17 Oct 2023 09:17

Hansa publishes strong results 5-year after a kidney transplant supported by Idefirix. The follow up results includes 90% patient survival and 82% graft survival and a very high safety outcome from year one to year five. Our point is that this is very interesting ahead of the publication of the AMR results which are due later in H2 2023. This could support the usage of Idefirix in an acute setting with no viable alternatives.

Länk till analysen i sin helhet: https://www.redeye.se/research/947325/hansa-biopharma-5-year-efficacy-support-for-imlifidase-idefirix-ahead-of-the-amr-publication?utm_source=finwire&utm_medium=RSS

Nyheter om Hansa Biopharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!